Clinical Study

The Effectiveness of Pre- and Postoperative Infliximab in Controlling Behçet’s Disease Posterior Uveitis in Patients Undergoing Vitrectomy: A Preliminary Study

Hossam El Din Mohamed Khalil,1 Heba A. El Gendy,2 Hala Ahmed Raafat,3 Hazem Effat Haroun,1 Tamer Atef Gheita,3 and Hossam Mahmoud Bakir1

1Department of Ophthalmology, Faculty of Medicine, Beni Sweif University, Beni Sweif, Egypt
2Department of Ophthalmology, Faculty of Medicine, Cairo University, Giza, Egypt
3Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Giza, Egypt

Correspondence should be addressed to Heba A. El Gendy; hebagendy2000@gmail.com

Received 24 October 2016; Revised 4 February 2017; Accepted 8 February 2017; Published 4 April 2017

Academic Editor: Suphi Taneri

Copyright © 2017 Hossam El Din Mohamed Khalil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To evaluate the short-term effectiveness of infliximab in controlling ocular manifestations in Behçet’s Disease (BD) patients candidate for pars plana vitrectomy, if given in a regimen before and after the planned procedure.

Patients and Methods. 30 eyes of 27 adult male BD patients with a mean age of 35.56 yrs presented with refractory posterior uveitis not responding to immunosuppressive drugs and candidate for vitrectomy were included. Infliximab was given in a dose of 5 mg/kg intravenous infusion once every two weeks for 3 treatment sessions before the intended vitrectomy followed by 3 treatment sessions at two-week intervals, after vitrectomy.

Results. Improvement of ocular manifestations was noted in all eyes, with complete resolution in 26 eyes (87%). Visual acuity improved from 0.23 ± 0.11 to 0.38 ± 0.17 (p ≤ 0.02), ESR decreased from 65.92 mm/hr ± 17.32 SD to 24.93 mm/hr ± 5.28 SD at the last treatment cycle (p ≤ 0.01). The mean daily dose of systemic corticosteroids was tapered from 44.54 mg/d ± 2.89 to 8.48 mg/d ± 6.38 (p ≤ 0.02), and no relapses were noted during the follow-up period.

Conclusion. Infliximab may be safe and effective in controlling posterior uveitis and inducing remissions if given in a regimen before and after vitrectomy in BD patients.

1. Introduction

Behçet’s disease (BD) is a chronic multisystem inflammatory disorder with ocular involvement in 30–70% of cases. Ocular manifestations may present as anterior uveitis and more commonly as posterior or panuveitis, whereas vasculitis remains the main pathology leading to vision-threatening complications [1–3].

Different treatment modalities have been proposed in BD in which the primary goal of treatment is to control the disease activity and to induce long-term remissions, whereas corticosteroids and other immunosuppressive agents have been proposed as the cornerstone for treatment [4].

Tumor necrosis factor (TNF-α) is an inflammatory cytokine that has been noted in uveitis-induced experimental animal studies, together with other cytokines, with documented increased serum and aqueous humor levels in the eyes with active posterior uveitis, whereas the blockade of these inflammatory mediators has been postulated to provide better control in BD patients by many investigators [5, 6].

Infliximab, a monoclonal antibody to TNF-α, is a biologic agent that has been approved for use in rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis and has been proposed for the treatment of different types of ocular inflammation through binding and neutralizing the effect of TNF-α, with promising results [7].
According to EULAR recommendations, infliximab or cyclosporine A, in combination with azathioprine or interferon-alpha together with corticosteroids, has been recommended for the treatment of ocular Bechet’s disease with severe posterior segment involvement [8].

The aim of this work is to evaluate the short-term efficacy of intravenous infliximab in controlling ocular manifestations in BD patients who are candidates for vitrectomy, if given in a regimen before and after the planned procedure.

2. Patients and Methods

2.1. Study Population. The current study protocol proceeded in accordance with the ethical standards in the Declaration of Helsinki 1964 [9].

In this prospective, nonrandomized, interventional series of cases, 30 eyes of 27 adult male BD patients, aged from 27 to 42 years (mean 35.56 ± 5.11 SD), with a disease duration ranging between 3.5 and 10.5 years (mean 7.05 ± 2.22 SD) were included in the recruitment from patients attending the rheumatology and rehabilitation and ophthalmology outpatient clinics and inpatient department in Kasr-Al-Aini and Beni-Sweif faculty hospitals, during the period from February 2014 to January 2016 (ISRCTN registry ISRCTN20489230).

All patients were candidates for pars plana vitrectomy due to their refractory posterior uveitis not responding to immunosuppressive drugs.

All patients were requested to sign an informed consent at the start of the current study regarding their acceptance of participation, the detailed surgical procedure and the protocol of medications as well as the follow-up protocol, and the possible complications.

2.2. Data Collection and Clinical Assessment. Full history taking, regarding the disease manifestations, disease duration, and previous immunosuppressant therapy, was implemented. Current medications received by the patients were considered, and patients receiving corticosteroids for management of their disease were not excluded. Full comprehensive clinical examination and skin pathergy test were conducted for all participants, whereas the diagnosis of BD was confirmed based upon satisfying the set of diagnostic criteria published by the International Study Group for Behçet’s disease in 1990 [10].

2.3. Investigations. Blood specimens were collected after an overnight fast. All patients had the following laboratory investigations prior to the initiation of the first injection and prior subsequent doses to monitor drug-related side effects, that is, complete blood count, liver function tests, platelet count, erythrocyte sedimentation rate, antinuclear antibody level, renal function tests. Chest X-ray was performed in the study to exclude chest infection or TB, as well as tuberculin skin test, where patients with negative skin tests were only included.

2.4. Ophthalmological Examination. All patients underwent a full ophthalmologic examination, that is, best-corrected visual acuity (BCVA) testing, slit-lamp anterior segment examination, slit-lamp biomicroscopy, tonometry, and indirect ophthalmoscopy. Other investigations including fundus photography, fluorescein angiography, and ultrasonography were performed as indicated.

2.5. Indications of Pars Plana Vitrectomy. The eyes with refractory posterior uveitis not responding to immunosuppressive drugs, associated with dense vitreous opacities interfering with visual potentials, epiretinal membranes with associated cystoid macular edema (CME), or impending traction on the retina, were recruited thereafter for the proposed treatment protocol.

2.6. Exclusion Criteria. Patients were excluded when they had concurrent active infection, end-stage disease with no light perception attributable to retinal ischemia or optic atrophy, history of tuberculosis, positive tuberculin skin test, or bilateral irreversible blindness, impaired liver functions, leucopenia, and thrombocytopenia. Patients receiving immunosuppressant drugs other than corticosteroids were excluded as well.

2.7. Exposure. Infliximab was given in a dose of 5 mg/kg intravenous infusion over a three-hour period once every two weeks for 3 treatment sessions prior to the planned pars plana vitrectomy, after stoppage of other immunosuppressant drugs and keeping the patients on their pre-exposure daily doses of corticosteroids. All patients underwent vitrectomy operation, and vitreous opacities as well as epiretinal membranes were managed accordingly. Infliximab was then given in a dose of 5 mg/kg intravenous infusion once every two weeks for 3 treatment sessions after the surgical intervention.

Patients were observed for 1 hour after stopping infusion for adverse effects. Infusions were followed by maintenance treatment of oral prednisone that was tapered accordingly. No patients were treated with topical steroids or retrobulbar steroid injections.

2.8. Follow-Up. Patients were followed up for a mean period of 16.06 ± 1.96 weeks following the last treatment cycle. The primary outcome parameters were a clinical response to treatment measured as change in best-corrected visual acuity (BCVA) using a Snellen chart (on a scale of 10), signs of inflammatory activity, adverse events, reduction in concomitant corticosteroid requirements, and reduction in ESR. Unexpected complaints and complications were recorded as adverse events. The exceptions were mild flu-like illness and mild injection site erythema.

The results before the initiation of the first treatment cycle were compared with those at the end of the follow-up period. Moreover, the disease activity was defined as cells and flare in the anterior chamber, vitreous cells, retinal perivasculare sheathing, retinal infiltraion, new retinal hemorrhages, or optic papillitis, according to the Standardization of Uveitis Nomenclature (SUN) Working Group terminology [11].

2.9. Statistical Analysis. All statistical calculations and analyses were done using computer program SPSS (Statistical
Table 1: Demographic data and clinical presentations.

| Demographic data       | Mean ± SD  | Range     |
|------------------------|------------|-----------|
| Age (years)            | 35.56 ± 5.11 | 27–42     |
| Duration (years)       | 7.05 ± 2.22  | 3.5–10.5  |

Clinical presentations

| Ocular manifestations | %          |           |
|-----------------------|------------|-----------|
| Anterior uveitis      | 5          | 18.5%     |
| Posterior uveitis     | 27         | 100%      |
| Vitreous cells & opacities | 27 | 100%      |
| Retinal vasculitis    | 5          | 18.5%     |
| Epiretinal membranes  | 8          | 29.6%     |
| CME                   | 2          | 7.4%      |

Extraocular manifestations

| %          |           |
|------------|-----------|
| 15         | 55.6%     |

Table 2: The average daily doses of preoperative medications.

| Medications    | N  | %     | Dose*   |
|----------------|----|-------|---------|
| Corticosteroids| 27 | 100%  | 44.54 ± 2.89 |
| Cyclosporin A  | 7  | 26%   | 200 ± 33.66  |
| Colchicine     | 20 | 74%   | 0.93 ± 0.3   |
| Azathioprine   | 5  | 18.5% | 139.4 ± 19.5 |
| Cyclophosmaide | 5  | 18.5% | 719 ± 48.01  |

*mg/day.

Table 3: Daily dose of corticosteroids, before and after infliximab treatment in the BD patients.

| Daily dose | Before infliximab | After infliximab | p value |
|------------|-------------------|------------------|---------|
| Min        | 36.02             | 0                |         |
| Max        | 48.5              | 20               |         |
| Mean       | 44.54 ± 2.89      | 8.48 ± 6.38      | ≤0.2    |

*mg/day.

In 4 eyes, a failure to achieve complete resolution of inflammatory manifestations in the form of persistence of anterior chamber and vitreous cells was noted, despite the relative improvement as compared to the initial pre-treatment condition.

All the eyes showed an improvement of BCVA by 1–3 lines on a Snellen chart (mean 2.23 ± 0.67), and the mean BCVA improved from 0.23 ± 0.11 to 0.38 ± 0.17 by the end of the follow-up period that was considered not statistically significant (p ≤ 0.2).

ESR considerably decreased from a mean pretreatment value of 65.92 mm/hr ± 17.32 SD to a mean value of 24.93 mm/hr ± 5.28 SD by the end of the last treatment cycle (p ≤ 0.1).

The mean daily dose of systemic corticosteroids was tapered throughout the follow-up period in all patients with stoppage of systemic corticosteroids achieved in 5 patients (18.5%) by the end of the follow-up period. The detailed pre- and posttreatment corticosteroid doses are shown in Table 3.

No eyes showed signs of reactivation, that is, relapses throughout the follow-up period, and the introduction of additional treatment modalities was not needed in any of the participants as well.

Regular monitoring of patients throughout the treatment course revealed no serious complications necessitating the discontinuation of intravenous infliximab infusion, whereas the proposed treatment protocol was conducted in all the recruited participants.

4. Discussion

The procedure of pars plana vitrectomy has been advocated in selected cases with intractable posterior uveitis in BD patients not responding to different treatment modalities including immunosuppressant agents and/or with the development of sight-threatening complications, that is, epiretinal membranes with tractional detachment that the persistence
of vitreous components has been postulated to reactivate secondary immune response, with its high levels of inflammatory cytokines [12, 13].

The role of T lymphocytes in the pathogenesis of BD and the documentations of high serum levels of inflammatory cytokines in patients with active disease as well as in aqueous samples of the eyes with activity has been postulated by many investigators, whereas tumor necrosis factor-alpha (TNF-α), an inflammatory cytokine, proved to have a role in the disease activity, which highlight the role of biologic agents, for example, infliximab as a promising treatment modality in intractable cases, through binding TNF-α and its soluble receptors [14, 15].

Despite being highly effective in cases with severe ocular inflammatory conditions and retinal involvement, the high cost effect of the drug infliximab might stand as a limitation in considering the drug in the treatment protocols of patients with ocular Bechet in developing countries.

Another questionable issue regarding the use of infliximab is the necessity of a maintenance treatment protocol after the initial control of the ocular condition to prevent relapses, which again raised the high cost effect problem for the use of the drug in centers with no governmental medical insurance [16, 17].

In the present study, we evaluated the effectiveness of a proposed treatment regimen in the BD eyes scheduled for vitrectomy due to intractable vitritis not responding to medical treatment, in the form of 3 preoperative treatment cycles followed by 3 postoperative maintenance cycles with 2-week intervals, in controlling ocular inflammatory response and inducing long-term remissions.

To our knowledge, this is the first study considering the evaluation of the efficacy of pre- and postvitrectomy infliximab in controlling cases with posterior uveitis resistant medical treatment in BD patients.

In the current study, all the eyes showed considerable improvement in ocular symptoms and signs of inflammation with 87% of the eyes showed complete resolution by the end of the follow-up period. Moreover, a decline in ESR values, denoting the relative control of the inflammatory cascade, was achieved in all patients.

A considerable result in our work is that the daily corticosteroid dose was tapered in all cases according to ocular and systemic conditions and was stopped in 5 patients by the end of the follow-up period, without the documentation of any activity after reducing or even discontinuing the daily dose of corticosteroids.

Despite the debate regarding the safety and efficacy of vitrectomy in the eyes with active inflammation, with published reports documenting the occurrence of severe inflammations postvitrectomy, as well as the reported risk of postoperative hypotony [18–20], our results seemed to be promising with good control of the inflammatory process in all cases.

The results in the current study are still comparable with the data published by Heiligenhaus et al. [21], who recommended a preoperative control of intraocular inflammation prior to the vitrectomy procedure to decrease the risk of complications, and Mesquida et al., with reported favorable results following pars plana vitrectomy in the Bechet eyes with no reported postoperative complications and recorded control of ocular inflammatory condition and the reduce in postvitrectomy systemic treatment [22].

Our results, regarding the efficacy of infliximab in controlling ocular inflammatory conditions, improving VA, and its influence on other immune suppressants, with subsequent tapering of systemic doses of corticosteroids used by all patients after the administration of infliximab, are comparable with published data by many investigators [17, 23–26].

In the present study, no relapses were recorded throughout the follow-up period, that is, 16.09 weeks after the last treatment cycle, which is not comparable with previous published data that reported the occurrence of relapses at a reduced rate following either pars plana vitrectomy or infliximab therapy [15–17, 21].

In our opinion, the occurrence of no relapses in the present study may be attributed to both the combination of pars plana vitrectomy with subsequent removal of cytokines loaded vitreous and the initiation of preoperative infliximab therapy aiming for preoperative control of the inflammatory activity, followed by postoperative treatment cycles.

5. Conclusions

In our experience, infliximab may be safe and effective in controlling posterior uveitis if given in a regimen before and after vitrectomy in BD patients allowing the reduction of corticosteroids and immunosuppressive drugs required to control the disease, as well as in inducing long-term remission; however, a proper patient selection and meticulous follow-up during the treatment course should be considered to overcome the drug adverse reactions, for example, infections.

Despite being statistically not significant, however, the clinical improvement in BCVA, the decreased ESR values, the reduced corticosteroids’ daily doses, and the experience of no relapses after the discontinuation of the drug may encourage the proposed treatment regimen in cases candidate for surgical intervention with possible promising results.

Further studies regarding this proposed treatment regimen on a larger number of patients as well as longer follow-up periods are recommended for further evaluation of the long-term results particularly its influence on the rate of relapses and the necessity of maintenance doses of infliximab to stabilize the disease condition.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] H. Behçet, “Uber rezidivierende Aphthose, durch ein Virus verursachte Geschwure in Mud, am Ague and an den Genitalien,” Dermatologische Wochenschrift, vol. 105, no. 36, pp. 1152–1157, 1937.

[2] R. Oktry Kacmaz, J. H. Kempen, C. Newcomb et al., “Ocular inflammation in Behçet’s disease: incidence of ocular
complications and loss of visual acuity,” *American Journal of Ophthalmology*, vol. 146, no. 6, pp. 828–836, 2008.

[3] A. Al-Mujaini and U. K. Walli, “Frosted branch angiitis, neuroretinitis as initial ocular manifestation in Behcet disease,” *Indian Journal of Ophthalmology*, vol. 59, no. 3, pp. 240–241, 2011.

[4] A. A. Okada, “Immune-modulatory therapy for ocular inflammatory disease: a basic manual and review of the literature,” *Ocular Immunology and Inflammation*, vol. 13, no. 5, pp. 335–351, 2005.

[5] K. Koizumi, V. Poulaki, S. Doehman et al., “Contribution of TNF-α to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo,” *Investigative Ophthalmology & Visual Science*, vol. 44, no. 5, pp. 2184–2191, 2003.

[6] Y. Ozdamar, N. Barker, G. Bahar et al., “Inflammatory mediators and posterior segment involvement in ocular Behcet disease,” *European Journal of Ophthalmology*, vol. 19, no. 6, pp. 998–1003, 2009.

[7] L. SobrinE. C. Kim, W. Christen, T. Papadaki, E. Letko, and C. S. Foster, “Infliximab therapy for the treatment of refractory ocular inflammatory disease,” *Archives of Ophthalmology*, vol. 125, no. 7, pp. 895–900, 2007.

[8] G. Hatemi, A. Silman, D. Bang et al., “EULAR recommendations for the management of Behcet disease,” *Annals of the Rheumatic Diseases*, vol. 67, no. 12, pp. 1656–1662, 2008.

[9] World Medical Association, “World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects,” *Journal of the American Medical Association*, vol. 310, no. 20, pp. 2191–2194, 2013.

[10] International Study Group for Behcet’s Disease (ISG), “Criteria for diagnosis of Behcet’s disease,” *Lancet*, vol. 335, no. 8697, pp. 1078–1080, 1990.

[11] D. A. Jabs, R. B. Nussenblatt, J. T. Rosenbaum, and The Standardization of Uveitis Nomenclature (SUN) Working Group, “Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop,” *American Journal of Ophthalmology*, vol. 140, no. 3, pp. 509–516, 2005.

[12] C. J. Brinkman, A. J. Otto, and A. C. Breebaart, “Ocular inflammatory activity following different techniques of lens extraction and vitrectomy in rabbits,” *Current Eye Research*, vol. 9, no. 12, pp. 1137–1140, 1990.

[13] C. J. Brinkman, A. J. Otto, A. Kijlstra, and A. C. Breebaart, “The influence of vitrectomy and lensectomy on experimental uveitis,” *Current Eye Research*, vol. 9, supplement, pp. 125–130, 1990.

[14] B. Turan, H. Gallati, H. Erdi, A. Gürler, B. A. Michel, and P. M. Villiger, “Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet’s disease; soluble TNFR-75 as a biological marker of disease activity,” *The Journal of Rheumatology*, vol. 24, no. 1, pp. 128–132, 1997, (Abstract).

[15] K. F. Tabbara and A. I. Al-Hemidan, “Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease,” *American Journal of Ophthalmology*, vol. 146, no. 6, pp. 845–850, 2008.

[16] I. Tugal-Tutkun, A. Mudun, M. Urgancioglu et al., “Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease; an open-label trial,” *Arthritis and Rheumatism*, vol. 52, no. 8, pp. 2478–2484, 2005, (Abstract).

[17] M. Accorinti, M. P. Pirraglia, M. P. Paroli, R. Priori, F. Conti, and P. Pivetti, “Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease,” *Japanese Journal of Ophthalmology*, vol. 51, no. 3, pp. 191–196, 2007.

[18] W. F. Mieler, B. R. Will, H. Lewis, and T. M. Aaberg, “Vitrectomy in the management of peripheral uveitis,” *Ophthalmology*, vol. 95, no. 7, pp. 859–864, 1988.

[19] A. M. Petrilli, R. J. Belfort, M. T. Abreu, A. L. Lima, M. G. Amaral, and P. P. Bonomo, “Ultrasonic fragmentation of cataract in uveitis,” *Retina*, vol. 6, no. 1, pp. 61–65, 1986.

[20] H. W. J. Flynn, J. L. Davis, and W. W. Culbertson, “Pars plana lensectomy and vitrectomy for complicated cataracts in juvenile rheumatoid arthritis,” *Ophthalmology*, vol. 95, no. 8, pp. 1114–1119, 1988.

[21] A. Heiligenhaus, N. Bornfeld, M. H. Foerster, and A. Wessing, “Long term results of pars plana vitrectomy in the management of complicated uveitis,” *British Journal of Ophthalmology*, vol. 78, no. 7, pp. 549–554, 1994.

[22] M. Mesquida, L. Pelegrin, V. Llorec et al., “Pars plana vitrectomy for vitreoretinal complications of Behcet uveitis,” *European Journal of Ophthalmology*, vol. 23, no. 1, pp. 119–128, 2013.

[23] P. P. Sifakis, P. G. Theodossiadis, C. G. Katsiari, P. Kaklamannis, and N. N. Markomichelakis, “Effect of infliximab on sight-threatening panuveitis in Behcet’s disease,” *Lancet*, vol. 358, no. 9278, pp. 295–296, 2001, (Abstract).

[24] S. Munoñ-Fernández, V. Hidalgo, J. Fernández-Melón, A. Schlincker, and E. Martin-Mola, “Effect of infliximab on threatening panuveitis in Behcet’s disease,” *Lancet*, vol. 358, no. 9393, p. 1644, 2001.

[25] L. Niccoli, C. Nannini, M. Benucci et al., “Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease. A 24-month follow-up study,” *Rheumatology*, vol. 46, no. 7, pp. 1161–1164, 2007.

[26] S. Ohno, S. Nakamura, S. Hori et al., “Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet disease with refractory uveoretinitis,” *The Journal of Rheumatology*, vol. 31, no. 7, pp. 1362–1368, 2004.